据最新行业动态显示,东阳光药自主研发的低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)靶向新药HEC53856片,已在国内正式启动针对非髓系恶性肿瘤化疗相关性贫血的II期临床试验。这一里程碑事件标志着我国在肿瘤支持治疗领域迈出关键一步,若HEC53856片上市,不仅有望实现我国HIF-PHI药物的国产替代,还将重塑我国化疗性贫血的治疗模式,何为化疗相关性贫血(CIA)?CIA是恶性肿瘤治疗过程中最...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.